ClinicalTrials.gg
Status unknownNCT05745311Updated Feb 28, 2023

Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke

A Phase 2 interventional study of The KPCXM18 injection and Placebo in Acute Ischemic Stroke, sponsored by Kunming Pharmaceuticals, Inc.. Status unknown. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-28.

Sponsored by Kunming Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke and its PK/PD characteristics in patients.

02

Conditions studied

  • Acute Ischemic Stroke

Keywords

  • stroke
03

In context

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

This study's planned enrollment of 240 is above the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Kunming Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 80 years old (including 18 years old and 80 years old), male or female;
  2. Diagnosed with acute ischemic stroke according to the "Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018";
  3. The time from the last normal behavior to the time of initiation of the drug infusion ≤ 48 hours. For stroke after waking up or when the time of symptom onset cannot be accurately obtained due to aphasia, consciousness disorder, and other reasons, the time of onset should take the last time the patient showed normally as standard;
  4. The patients who first attacked, or the patients who had a good prognosis after the last attacked ( mRS score was ≤1 before the onset of the disease );
  5. During the screening period, 4 points ≤ NIHSS score ≤ 24 points, and the sum of NIHSS fifth upper limb and sixth lower limb score ≥2 points;
  6. The subject or his guardian is aware of the study, and if the subject or his guardian is unable to read, the impartial witness reads the form and other written materials, witnesses the informed consent, voluntarily participates and signs the written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Patients with intracranial hemorrhagic diseases confirmed by head CT or MRI: hemorrhagic stroke, epidural hematoma, intracranial hematoma, ventricular hemorrhage, subarachnoid hemorrhage, etc;
  2. Patients with disturbance of consciousness (NIHSS score Ia ≥2 points);
  3. Patients who need or have undergone intravenous thrombolysis or endovascular interventional therapy (including endovascular mechanical thrombectomy, intravascular thrombus aspiration, arterial thrombolysis, angioplasty and stenting, etc.) or patients with arteriovenous bridging therapy after this onset;
  4. Patients with malignant tumors, serious diseases of blood, digestion or other systems or diseases with bleeding tendencies (such as hemophilia, etc.), and the expected survival time is not more than 3 months;
  5. Patients with a history of major surgery within 1 month before screening;
  6. Patients with severe hypertension (systolic blood pressure ≥ 200 mmHg or diastolic blood pressure ≥110 mmHg) that cannot be controlled after treatment;
  7. Patients with heart rate \< 40 beats/min and/or ventricular rate > 120 beats/min; Patients with 2nd and 3rd degree heart blocks without pacemakers or other malignant arrhythmias; Patients with acute myocardial infarction, cardiac interventional therapy, or heart failure (grade III and IV according to ) within the past 1 month;
  8. Patients with severe liver function impairment, or , AST > 2.0 times the value (ULN);
  9. Patients with severe renal impairment, or serum creatinine (Cr) > 1.5× ULN;
  10. Patients who have used neuroprotective drugs (including commercially available edaravone, edaravone and dexborneol, nimodipine, gangliosides, piracetam, oxiracetam, butylphthalide, etc.) after the onset of this illness, as well as other traditional Chinese medicine labels containing the effect of treating acute ischemic stroke (cerebral infarction);
  11. Patients with other psychiatric diseases and limb disorders, including severe mental disorders, dementia and other combined diseases that may affect neurological function tests;
  12. Patients with a history of alcohol or drug abuse;
  13. Patients with allergies, to citicoline, KPCXM18 or ;
  14. Pregnancy, lactation. or patients who have a family plan within 3 months of the first dose and who are unwilling to use ;
  15. Patients who participated in or are currently participating in other clinical trials within 1 month prior to this study;
  16. The investigator considers that patients are not suitable for clinical trials
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    low-dose group (The KPCXM18 injection)

    Intravenous infusion of 20 mg twice daily at intervals of 12±2 hours for 10 days.

    Drug: The KPCXM18 injection

  • Experimental
    middle-dose group (The KPCXM18 injection)

    Intravenous infusion of 60 mg twice daily at intervals of 12±2 hours for 10 days.

    Drug: The KPCXM18 injection

  • Experimental
    high-dose group (The KPCXM18 injection)

    Intravenous infusion of 100 mg twice daily at intervals of 12±2 hours for 10 days.

    Drug: The KPCXM18 injection

  • Placebo comparator
    Placebo

    Intravenous infusion twice a day with an interval of 12±2 hours for 10 days.

    Drug: Placebo

Interventions

  • DrugThe KPCXM18 injection

    Intravenous infusion

  • DrugPlacebo

    Intravenous infusion

06

What researchers measure

Primary outcomes

  1. Change in NIHSS score from baseline at day 10 after administration

    The National Institute of Health stroke scale(NIHSS) score ranging from 0-42. Higher score indicates worse function.

    Time frame: day 10

Secondary outcomes

  1. Proportion of subjects with mRS score ≤ 1 at day 90±7 after administration

    The Modified Rankin Scale(mRS) score ranging from 0-5. Higher score indicates worse function.

    Time frame: day 90±7

  2. Change in BI score from baseline at day 90±7 after administration

    The Barthel Index score ranges from 0 to 100, the higher scores mean a better outcome.

    Time frame: day 90±7

  3. Change in EQ-5D score from baseline at day 90±7 after administration

    Time frame: day 90±7

  4. Changes in NIHSS score from baseline on days 30±3 and 90±7 after administration

    The National Institute of Health stroke scale(NIHSS) score ranging from 0-42. Higher score indicates worse function.

    Time frame: days 30±3 and 90±7

  5. Changes in mRS score from baseline on days 30±3 and 90±7 after administration

    The Modified Rankin Scale(mRS) score ranging from 0-5. Higher score indicates worse function.

    Time frame: days 30±3 and 90±7

  6. The proportion of subjects whose NIHSS score improved by ≥4 points at days 10, 30±3 and 90±7 after administration

    The National Institute of Health stroke scale(NIHSS) score ranging from 0-42. Higher score indicates worse function.

    Time frame: days 10, 30±3 and 90±7

  7. Proportion of subjects with recurrence of stroke within 90±7 days after administration

    Time frame: within 90±7 days

  8. Changes in serum biomarkers (TNF-α, MMP9, CHE, IL-10, S100-β) from baseline on day 7 after administration

    Time frame: day 7

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2023; primary completion for May 2024, 14 months later.

Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's planned 14 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2023
First posted
Feb 27, 2023
StartEst.
Mar 1, 2023
Primary completionEst.
May 1, 2024
CompletionEst.
Jul 30, 2024
Last update
Feb 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05745311
Lead sponsor
Kunming Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Feb 27, 2023
Start date
Mar 1, 2023 (estimated)
Primary completion
May 1, 2024 (estimated)
Completion
Jul 30, 2024 (estimated)
Last update
Feb 28, 2023

Study contacts

Duo Gao, bachelor
Contact
duo.gao@kpc.com.cn
0871-68319868-3052
Yongjun Wang, MD
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion